Active clinical trials for "Heart Diseases"

To characterize the epidemiology and genetics of apolipoproteins A-I, A-II, B, C-II, C-III, and E in a population of Mexican-Americans in Starr County, Texas.

To determine why Black Americans have a higher prevalence of hypertension than whites by examining the interactions of psychosocial stressors and suppressed hostility with genetic or constitutional factors.

To relate observations at the DNA level to the distribution of coronary heart disease in the population at large.

To determine the combined effects of job strain and social isolation on cardiovascular morbidity and mortality.

To determine if silent myocardial ischemia was associated with an increased risk of cardiac mortality and morbidity during a one to three year follow-up in patients with coronary heart disease.

To investigate possible mechanisms responsible for the decline in cardiovascular disease mortality among the Framingham Heart Study population and to evaluate the health status of survivors in terms of subsequent illness and functional limitations.

To define the incidence and prevalence of AIDS-associated cardiomyopathy. Also, to conduct immunopathology and serologic studies in endomyocardial biopsies and autopsy tissues.

To develop natural history data regarding the incidence, clinical course, prognosis, and effects of treatment with anti-viral and immunosuppressive agents on HIV-associated heart disease. A second part of the study evaluated a number of possible mechanisms underlying the development of HIV heart disease.

To define the role of dietary variables on changes in plasma cholesterol levels over time in the Framingham cohort and the Framingham Offspring cohort.

To determine whether low total urinary kallikrein activity was prospectively associated with new hypertension onset or elevated blood pressures.